Skip to main navigation
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact

Webinars

Clene Inc. Presentation of CNM-Au8 Topline Data From the HEALEY ALS Platform Trial
Oct 3, 2022
Webcast
Clene Inc. – Phase 2 VISIONARY-MS Trial Results
Aug 15, 2022
Webcast
Clene Inc. Presentation of RESCUE-ALS Topline Clinical Trial Results
Nov 2, 2021
Webcast
Supporting Materials
Presentation 23.4 MB
Expert Perspectives Webinar - Cellular Energetic Failure: Addressing Unmet Needs and a New Investigational Treatment for ALS and MS
Jul 14, 2021
Webcast Replay
Supporting Materials
Clene Expert Perspectives 423.8 KB


1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved